2021
DOI: 10.1002/jmv.27005
|View full text |Cite
|
Sign up to set email alerts
|

Molecular characterization of HTLV‐1 genomic region hbz from patients with different clinical conditions

Abstract: The human T-cell lymphotropic virus type-1 (HTLV-1) is associated with severe pathologies, such as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), adult T-cell leukemia-lymphoma (ATLL), and infective dermatitis associated with the HTLV-1 (IDH). Interestingly, HTLV-1 infection does not necessarily How to cite this article: Cucco MS, de Moraes LEP, de Oliveira Andrade F, et al. Molecular characterization of HTLV-1 genomic region hbz from patients with different clinical conditions.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 23 publications
0
1
0
Order By: Relevance
“…Infected individuals can develop HTLV-1-associated pathologies such as adult T-cell leukemia/lymphoma (ATLL in 2-5% of patients), HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP in 0.25-3.8% of patients), HTLV-1-associated infectious dermatitis (IDH), and other inflammatory diseases such as uveitis and pneumonitis, or they can be classified as asymptomatic carriers [5][6][7]. The factors involved in the development of a particular clinical manifestation have not yet been elucidated, and HTLV-1-infected individuals remain without specific treatment [8][9][10].…”
Section: Introductionmentioning
confidence: 99%
“…Infected individuals can develop HTLV-1-associated pathologies such as adult T-cell leukemia/lymphoma (ATLL in 2-5% of patients), HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP in 0.25-3.8% of patients), HTLV-1-associated infectious dermatitis (IDH), and other inflammatory diseases such as uveitis and pneumonitis, or they can be classified as asymptomatic carriers [5][6][7]. The factors involved in the development of a particular clinical manifestation have not yet been elucidated, and HTLV-1-infected individuals remain without specific treatment [8][9][10].…”
Section: Introductionmentioning
confidence: 99%